Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

How did multifaceted support from across Inizio help a biotech firm prepare for launch?

April 13, 2026 |  

Discover how teams from across Inizio provided a range of integrated services to give a client’s product the best chance of launch success.

- PMLiVE

Discover how teams from across Inizio provided a range of integrated services to give a client’s product the best chance of launch success – including market analysis, sales teams, MSLs, training, launch meeting support, congress experiences, and product value demonstration.   

Our client is a US biotechnology company that specializes in developing therapies for complex and chronic conditions. For many years, the firm has been working on what’s become the first new FDA-approved therapy of its kind in almost two decades.  

Our client’s landmark product is an easy-to-use therapy that allows for rapid absorption and targets various receptors. In clinical trials, the treatment was shown to significantly reduce pain. 

Primarily, the client needed a commercialization partner to rapidly set up a large, flexible nationwide sales team ready for the product launch in October 2025. 

Read the full case study here.

This content was provided by Inizio

Company Details

- PMLiVE

Inizio

Email
Website

 Latest Content from  Inizio 

Demand assessment research video

Head of Business Analytics Tom Nolte and Associate Director Will Tolley discuss demand assessment research – the various techniques and when in a product’s stage of development a demand assessment…

Men vs Women in emerging markets

Our latest interactive infographic compares male vs female health characteristics in the BRIC emerging marketS

South Korea: The next global player?

In this paper, we will explore some of the key trends and outlooks for South Korea in more detail, including what lies behind its presence at the extremes of two…

20 questions: Round 4

As it’s our 20th year anniversary, we invited our employees to play our version of 20 questions – this month “What’s been the funniest thing to happen to you whilst you’ve…

Will gene therapies finally be commercially viable to pharma?

Our latest Free Thinking white paper explores the science behind the idea of gene therapy and takes a look at some of the core challenges medical researchers have faced when…

Wargaming in HCV

The challenge:Our client had a product ready for launch in the HCV landscape. A number of new competitor products were expected to alter the market dynamics. Given the stage of…

Living with Lupus: Breaking the Silence

Published in eyeforpharma July 2017 by Mariel Metcalfe

Demystifying human-centred design: the application of iterative, human-centric approaches in global health market research

One of the biggest buzz topics in the global health community over the last couple of years has been human-centred design, also referred to as behaviour-centred design. In this blog…

In the news: What will the UK’s recent general election result and ongoing Brexit negotiations mean for DfID funding for global health?

The UK’s Department for International Development (DfID) was established in 1997 with a mandate to tackle world poverty. Since its inception, it has played a major role in the global…

TRIO OF HIRES SIGNAL PEGASUS’ NORTHERN GRIT

Growth trend continues at ‘health first, sector second’ agencyPegasus, an Ashfield company, part of UDG Healthcare plc, has announced further growth of its Pharma and Life Sciences division with the…